What is known and objective: Adverse drug reaction reporting in the UK is lower than expected based on epidemiological data. This study aims to explore (a) nonmedical prescribers' (NMP) confidence in identifying and reporting ADRs, (b) NMP prescribing habits and engagement with the Yellow Card Scheme (YCS) and (c) NMP desire for future training in the identification and reporting of ADRs.
| WHAT IS K NOWN AND OBJEC TIVE
Adverse drug reactions (ADRs) are common. Epidemiological data from the UK suggest that ADRs are responsible for significant healthcare utilization accounting for 6.5% of hospital admissions. 1 ADRs are detected throughout the course of drug development, but these usually tend to be the commoner and milder reactions. The more serious ADRs are often not detected until the drug is licensed and used in larger population groups. Furthermore, the pattern of ADRs, even milder reactions, may change once the drug is marketed as its use in a real-world setting will lead to exposure to a wider group of patients (for example, the elderly, those with concomitant disease, those on interacting drugs and off-label use). [2] [3] [4] Postmarketing surveillance is therefore essential to ensure that the risk-benefit profile of a drug is monitored throughout its life cycle and to identify any new signals of ADRs as soon as possible.
The Yellow Card Scheme (YCS) was introduced in the UK in 1964
following the thalidomide disaster. 5 The system is the cornerstone of pharmacovigilance in the UK and is coordinated by the Medicines and Healthcare products Regulatory Agency (MHRA). The YCS relies on spontaneous reports which are used alongside data from postmarketing authorization studies and clinical trials to continuously update prescribing information. Identifying and reporting suspected
ADRs to the YCS are considered good practice for all healthcare professionals and are included within the competency frameworks which underpin prescribing practice for medical and nonmedical prescribers. 6 Nonmedical prescribing was introduced to allow healthcare professionals such as nurses, pharmacists, radiologists and physiotherapists to prescribe independently. Certification is gained through formal training, which generally consists of lectures and peer-supervised practice, and subsequent assessment. The qualification is recognized and reported by each of the profession-specific governing bodies (eg Royal College of Nursing). An independent nonmedical prescriber (NMP) theoretically can prescribe from the whole of the 
| Data collection
All of the participants were asked about their profession, qualifications, recent prescribing practice, ADR reporting and desire for future training in identifying and reporting ADRs. The flow of the rest of the questionnaire was then dependent upon the responses provided to certain questions. For example, answering "Yes" to "Have you ever reported an adverse drug reaction on a Yellow Card?" meant that participants were asked "Roughly how many Yellow
Cards have you submitted?".
| Statistical analysis
Descriptive statistics were performed on the whole sample (all responders) and on the two different groups (YC reporters and nonreporters NMPs; 41 incomplete questionnaires were rejected, leaving a total of 570 for analysis.
| RE SULTS AND D ISCUSS I ON

| Results
Of the 570 respondents, the majority were either nurses (68.1%) or community practitioners (eg district nurse and health visitor) For those who answered "no" to "Have you ever reported an adverse drug reaction on a Yellow Card?" we explored reasons preventing reporting to the YCS (question M). Thirty-eight (10.8%) individuals stated that reporting was not applicable. Although we cannot be certain, we believe that this is mainly because these professionals were not engaged with prescribing or patient contact in their current role, such as managerial/administrative positions. The most common reason given by all individuals (n = 261; 74.4%) who answered "no" to "Have you ever reported an adverse drug reaction on a Yellow Card?" was "I have never seen an adverse drug reaction."
Other reasons are summarized in Table 1 .
We attempted to gauge an understanding of identification of ADRs via Question J ( Table 2 ). The majority of respondents stated they were "confident" or "very confident" at identifying ADRs 
| Discussion
The Most participants agreed that their NMP course had left them feeling "very confident" at being able to detect ADRs and a similar proportion reported they were confident or very confident at identifying ADRs at the time of completing the questionnaire, which is a positive outcome given the high rates. Indeed, those with self-reported confidence in identifying ADRs were three times more likely to have submitted a Yellow Card. There was also a significant association between confidence and number of Yellow Cards submitted.
However, when our results are taken as a whole, this confidence in identifying and reporting ADRs is inconsistent with the fact that only 38.4% of the respondents had submitted a Yellow Card. It is known that the majority of healthcare professionals (including medical prescribers) do not report ADRs: indeed, a systematic review of 37 papers demonstrated that the median underreporting rate of ADRs was 94% (interquartile range: 82%-98%), with similar rates between medical prescribers and other healthcare professionals. 8 Moreover, a survey of 280 hospital pharmacists reported that 46%
had identified ADRs in the previous 6 months that should have been reported, 9 but only a small proportion (15%) did so. Additionally, one previous study of NMP engagement with pharmacovigilance found that almost half of respondents had reported ADRs to the YCS, although the last submission made by an individual was often before their NMP training was completed. 7 The design of our study is similar to that of Stewart and colleagues, and many of the outcomes complement these previous findings. 7 A common theme between both studies is respondents' lack of engagement with formal reporting despite high confidence and/or willingness to participate in pharmacovigilance. This disparity appears to be greater in the present study where the percentage of respondents reporting to the YCS was lower (38.4% vs 58.6%), lack of time to report, 10, 11 which may in fact demonstrate that ADR reporting is not a priority for most; (b) uncertainty regarding which drugs and/or reactions need to be reported 12, 13 ; (c) fear that submitting a suspected ADR that is subsequently disproved may cause embarrassment 14 ; (d) uncertainty whether a single report will make a contribution 15 ; and (e) fears regarding litigation if they have administered a prescription that resulted in an ADR. 15 There appears to be a difference in one attitudinal construct to reporting between medical prescribers and other healthcare professionals, in that medical prescribers are less likely to view reporting as another person's responsibility. Interestingly, primary care staff appear to be more likely to report than secondary care colleagues. 15, 16 In our survey, pharmacists were most likely to have ever reported to the YCS. Although the number of pharmacists represented in our survey is small (n = 27), it is consistent with a previous study, 7 perhaps reflecting the pharmacology training received by pharmacists alongside greater access to additional drug information as part of their daily workload. In our survey, the commonest reason for not reporting was that the respondent had never seen an ADR. This seems unlikely given the high prevalence of ADRs and probably indicates substantial uncertainty in identifying and recognizing ADRs in clinical practice.
Training is critical in improving pharmacovigilance practice in prescribers and is known to be a positive predictor for future reporting. 17 In our survey, although almost all respondents had received training in this area, this was largely delivered as part of another session, with only a minority having had a dedicated session on ADR reporting. We would recommend that those who organize courses, 
| WHAT IS NE W AND CON CLUS I ON
NMPs have an important role in drug safety and need to be encouraged to engage with formal pharmacovigilance systems such as the YCS. Training appears to give NMPs confidence to identify ADRs, but there seems to be a gap in actually identifying
ADRs given that most reported that they had never seen an ADR.
Strategies for improving the translation of theoretical knowledge about ADRs into practical skills in identifying ADRs, and subsequently reporting them, will be important. Minor modification of the current training courses to emphasize the importance of ADRs will be important in ensuring that future NMPs fully engage with spontaneous reporting systems such as the YCS. This survey has provided a baseline assessment to help direct future resource allocation in training and research provision. Further work is needed to add understanding to the gaps initially identified and subsequently explore interventions.
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